Cypherpunk Technologies

Cypherpunk Technologies P/CF

The P/CF (Price-to-Cash-Flow Ratio) of Cypherpunk Technologies (CYPH) as of Oct 17, 2026 is -0.67. In the previous year, P/CF (Price-to-Cash-Flow Ratio) was -0.92 — a change of -27.44% (higher).

P/CF

-0.67

YoY

-27.44%

Last updated:

P/CF (Price-to-Cash-Flow Ratio) of Cypherpunk Technologies is 2024 -0.67 . P/CF (Price-to-Cash-Flow Ratio) of Cypherpunk Technologies was 2023 -0.92 . It decreases by -27.44% higher compared to the previous year.

The Cypherpunk Technologies P/CF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/CF
Date
P/CF
Jan 1, 2017
-1.82 USD
Jan 1, 2018
-1.54 USD
Jan 1, 2019
-1.49 USD
Jan 1, 2020
-1.55 USD
Jan 1, 2021
-1.14 USD
Jan 1, 2022
-0.82 USD
Jan 1, 2023
-0.92 USD
Jan 1, 2024
-0.67 USD
The Cypherpunk Technologies P/CF history
YEARP/CFYoY
-0.67-27.44%
-0.92+12.09%
-0.82-28.32%
-1.14-26.17%
-1.55+3.64%
-1.49-3.23%
-1.54-14.97%
-1.82+14.46%
-1.59-68.02%
-4.96-3.18%
-5.13—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cypherpunk Technologies Stock analysis

What does Cypherpunk Technologies do? Cypherpunk Technologies Inc, trading under the ticker CYPH, is a biotechnology company based in Cambridge, United States. The company has a small workforce of six employees. It went public with an IPO on January 24, 2017. The company's website is https://www.leaptx.com/. The source description provided by the user contains unverified information, including the company's headquarters in Cambridge, Massachusetts, and details about its clinical stage programs, which are not confirmed by the facts provided. The source also mentions the company having 24 employees, which contradicts the provided employee count of six. Additionally, the source describes the company as developing monoclonal antibodies targeting cancer pathways, but these details are not part of the verified facts. The company's actual focus and product pipeline remain unconfirmed based on the information given. The source also incorrectly identifies the company as Leap Therapeutics, Inc., which is not the official name provided. The website provided, https://www.leaptx.com/, appears to be related to Leap Therapeutics, not Cypherpunk Technologies Inc. Therefore, the description is limited to the verified facts: the company's name, ticker, ISIN, country, city, sector, industry, employee count, IPO date, and website. No additional details about products, programs, or specific therapeutic targets can be included due to lack of verified information. Cypherpunk Technologies is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cypherpunk Technologies stock

P/CF (Price-to-Cash-Flow Ratio) of Cypherpunk Technologies is -0.67 in 2024.

P/CF (Price-to-Cash-Flow Ratio) of Cypherpunk Technologies changed from -0.92 to -0.67, representing a -27.44% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of P/CF (Price-to-Cash-Flow Ratio) Cypherpunk Technologies since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Cash-Flow ratio measures the stock price relative to operating cash flow per share. Unlike P/E, it is harder to manipulate as cash flow is less subject to accounting adjustments.

P/CF = Stock Price / Operating Cash Flow per Share

To evaluate P/CF (Price-to-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/CF (Price-to-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/CF (Price-to-Cash-Flow Ratio)'s Cypherpunk Technologies with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Cypherpunk Technologies

All Key Metrics — Cypherpunk Technologies